Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs MakeMyTrip Ltd — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while MakeMyTrip Ltd trades at $44.57 (market cap $4.09B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 3.1× MakeMyTrip Ltd's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and MakeMyTrip Ltd for 12 Days on average.
| HALO | MMYT | |
|---|---|---|
Market Cap | $12.58B | $4.09B |
Volume | 2,179,278 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $94.43 |
52-Week Low | $61.63 | $36.30 |
Typical Hold Time | 1 Days | 12 Days |
Enterprise Value | $14.49B | $4.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MMYT trades at $44.73, up 3.04% today, but technical indicators signal a bearish trend with support at $42. The stock shows mixed earnings, missing Q4 2025 and Q2 2026 estimates but beating Q1 2026. Revenue grew to $978.34M in 2025, though net income margin is thin at 3.23%. Analyst consensus is strongly bullish with a $77 price target, but cash flow turned negative in 2026, and debt-to-asset ratio surged, raising financial stability concerns.
The outlook is bifurcated: strong analyst support and a high target suggest upside, but deteriorating cash flow, rising leverage, and bearish technicals pose significant risks. Investors should weigh the potential from operational resilience and a planned Indian listing against financial volatility and macroeconomic pressures on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
